Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00390533 · ClinicalTrials.gov registry record · Phase 3
An Eight-week Study to Evaluate the Efficacy and Safety of 2 Doses of Saredutant in Patients With Generalized Anxiety Disorder
A Phase 3 study of Generalized Anxiety, sponsored by Sanofi.
- Completed
- Registry status
- Phase 3
- Development phase
- 428
- Enrollment target
- 2
- Study locations
NCT00390533: Completed Phase 3 study of Generalized Anxiety, sponsored by Sanofi.
NCT00390533 is a Phase 3 study of Generalized Anxiety that has completed, run by Sanofi. The registered enrollment target is 428 participants, above the 320-participant average among 3 other Generalized Anxiety trials with a reported enrollment target (34% higher). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00390533, a Phase 3 study of Generalized Anxiety, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 428 participants
- Enrollment target
- 2
- Study locations
Study Summary
The primary objective is to evaluate the efficacy of two fixed doses (100 mg and 30 mg once daily) of saredutant compared to placebo in patients with generalized anxiety disorder. The secondary objectives are to evaluate the efficacy of saredutant on disability and quality of life in patients with generalized anxiety disorder, and to evaluate blood levels of saredutant.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Saredutant
Study Locations (2)
New Jersey
- Sanofi-Aventis Administrative Office - Bridgewater
Other
- Sanofi-Aventis Administrative Office - Macquarie Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 428 participants |
| Start Date | 2006-09 |
| Est. Completion | 2008-02 |
| Phase | Phase 3 |
What the finished NCT00390533 record still lists
NCT00390533 is an interventional study that assigns participants to a tested intervention. The registered 428 participants enrollment target is mid-sized for trials with a published cap, above the 320-participant average among 3 other Generalized Anxiety trials with a reported enrollment target (34% higher).
The record links to 1 condition, with Generalized Anxiety appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00390533 reports a single indexed study location in New Jersey, Other.
Frequently Asked Questions
What is clinical trial NCT00390533 about?
NCT00390533 is a clinical study titled "An Eight-week Study to Evaluate the Efficacy and Safety of 2 Doses of Saredutant in Patients With Generalized Anxiety Disorder". The primary objective is to evaluate the efficacy of two fixed doses (100 mg and 30 mg once daily) of saredutant compared to placebo in patients with generalized anxiety disorder. The secondary objectives are to evaluate the efficacy of saredutant on disability and quality of life in patients with g...
What is the current status of trial NCT00390533?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 428 participants. The study started on 2006-09. Estimated completion is 2008-02.
What conditions does trial NCT00390533 study?
This clinical trial studies the following conditions: Generalized Anxiety.
What interventions are being tested in trial NCT00390533?
The interventions under investigation include: Placebo (DRUG), Saredutant (DRUG).
Who is sponsoring clinical trial NCT00390533?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00390533 being conducted?
This trial has 2 study locations across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Generalized Anxiety
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05566431 · 428 participants · NA
Benchmark Evidence Led by Latin America: Trial of Intracranial Pressure - Pediatrics
- NCT05646316 · 428 participants · Phase 3
Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Stage I Endometrial Cancer
- NCT05797610 · 428 participants · Phase 3
A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression
- NCT06073626 · 428 participants · NA
Addressing Genomic Disparities in Cancer Survivors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia